

Europäisches Patentamt

European Patent Office

Office européen des brevets



(1) Publication number:

0 513 702 A3

## (1Z)

## **EUROPEAN PATENT APPLICATION**

(21) Application number: 92107865.5

(51) Int. CI.5 A61K 31/40

(22) Date of filing: 11.05.92

(\$\hat{\infty}\$) Priority: **13.05.91 IT MI911299** 

Date of publication of application: 19.11.92 Bulletin 92/47

Designated Contracting States:

AT BE CH DE DK ES FR GB GR IT LI LU MC

NL PT SE

Date of deferred publication of the search report: 25.11.92 Bulletin 92/48

Applicant: Biella, Gabriele Strada Cà della Terra, 40 I-27100 Pavia(IT) Applicant: Fraschini, Franco Via Nerino, 3 I-20123 Milan(IT) Applicant: Stanvok, Bojidar

> Via Apollodoro, 6 I-20129 Milan(IT) Applicant: Ferini Strambi,

Applicant: Ferini Strambi, Luigi Via Caterina da Forli, 28 I-20146 Milan(IT)
Applicant: IFLO-ISTITUTO FARMACOLOGICO
LOMBARDO S.A.S., di Giorgio e Aldo Laguzzi
Via Prandina, 7

Inventor: Biella, Gabriele
Strada Cà della Terra, 40
I-27100 Pavia(IT)
Inventor: Fraschini, Franco
Via Nerino, 3

I-20128 Milan(IT)

I-20123 Milan(IT) Inventor: Stankov, Bojidar Via Apollodoro, 6

I-20129 Milan(IT) Inventor: Ferini Strambi, Luigi Via Caterina da Forli, 28

I-20146 Milan(IT)

Representative: Gervasi, Gemma, Dr. et al NOTARBARTOLO & GERVASI Srl 33, Viale Bianca Maria I-20122 Milano(IT)

- $\widehat{\underline{\mathscr{Z}}}$ ) Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication.
- (2) The present invention relates to new pharmaceutical compositions active in the therapy of sleep disorders comprising N-acetyl-5-methoxy-triptamine (melatonin) or one of its derivatives, preferably 2iodo-N-acetyl-5-methoky-triptamine iodomelatonin), 2-bromo-N-acetyl-5-methoxy-trip-(2-bromemelatonin), 2-chloro-N-acetyl-5methoxy-triptamine (2-chloromelatonin) or 6-chloro-N-acetyl-5-methoxy-triptamine (6-chloromelatonin), at a dosage comprised between 10 and 100 mg, preferably comprised respectively between 20 and 80 mg between 10 and 20 mg and between 10 and 40 mg alone or in association with a benzodiazepinic derivative at a dosage comprised between 0.06 and 25 mg.

EP 0 513 702 A3



## PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

92 10 7865

Category	Citation of document with in	DERED TO BE RELEV.	Relevant	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
X	EP-A-0 126 630 (MON		to claim	A 61 K 31/40
	* Whole document *			
Y	WO-A-8 901 472 (NEI CO.)		1-22	
	* Pages 1,2,4,5,8,9	•		
X	JOURNAL OF PINEAL RE 2, 1989, pages 205-2 Inc.; D. SUGDEN: "An of the melatonin and 2-iodomelatonin and in the juvenile Djur Phodopus sungorus cast Whole document *	ntigonadal activity alogs 2-chloromelatonin ngarian hamster,	1,4,10	
				TECHNICAL FIELDS SEARCHED (Int. Ct.5)
				A 61 K
				1
The Sear the provi out a me Claims so Claims n Reason fo In v Whic "ben sear	sions of the European Parent Convention aningful search into the state of the are earthed completely: earched incompletely: 1-22 of searched: or the limitation of the search: iew of the large h may be encompass zodiazepinic derich was limited to	European patent application does not conto such an extent that it is not possition the basis of some of the claims number of compour sed within the tevative" (claim 1) the compound merid examples (triaz	nds erm , the ntioned	
<del></del>	Place of search	Date of completion of the sear		Examiner
TH	E HAGUE	17-08-1992	GAC	G.
CATEGORY OF CITED DOCUMENTS  X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category		E : eartier pat after the f other D : document L : document	I: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons	
	chnological background			



## PARTIAL EUROPEAN SEARCH REPORT Application Number

EP 92 10 7865

	DOCUMENTS CONSIDERED TO BE RELEVA	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim		
Y	SLEEP, vol. 13, no. 3, June 1990, pages 232-244, Raven Press, Ltd, New York, US; G. COPINSCHI et al.: "Effects of the short-acting benzodiazepine triazolam, taken at bedtime, on circadian and sleep-related hormonal profiles in normal men"  * Whole document *	1-22		
Y	LIFE SCIENCES, vol. 40, no. 15, 17th April 1987, pages 1537-1543, Pergamon Journals Ltd, US; B. SURANYI-CADOTTE et al.: "Coexistence of central and peripheral benzodiazepine binding sites in the human pineal gland"  * Whole document *	1-22	TECHNICAL FIELDS SEARCHED (Int. Cl.5)	
A	ENDOCRINOLOGIA JAPONICA, vol. 33, no. 3, June 1986, pages 405-414; M. KABUTO et al.: "Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans" * Whole document *	1-22		
X	BIOCHEMICAL PHARMACOLOGY, vol. 40, no. 12, 15th December 1990, pages 2701-2705, Pergamon Press plc, Oxford, GB; L.P. NILES et al.: "Pharmacological inhibition of forskolin-stimulated adenylate cyclase activity in rat brain by melatonin, its analogs, and diazepam"  * Whole document *	1,4,6		